Core Viewpoint - Kaishikadi has successfully completed nearly 1 billion yuan in financing over the past 10 months, with the latest round raising approximately 500 million yuan, led by Zhongping Capital and supported by several notable investment institutions [2][3]. Company Overview - Established in 2017, Kaishikadi is a biotechnology company focused on diseases related to bile acid metabolism disorders. The company develops innovative drugs targeting nuclear receptors and G protein-coupled receptors (GPCRs), initially focusing on primary biliary cholangitis (PBC) and expanding into metabolic diseases such as metabolic-associated fatty liver disease (MASH), obesity, and diabetes [3]. Product Development - The core product CS0159 has received breakthrough therapy designation and orphan drug status from the FDA, achieving significant progress. The oral tablet has successfully completed Phase II trials for MASH in the U.S., and the Phase II core study for PBC in China has concluded with promising therapeutic potential, now advancing to Phase III trials [3]. - The research team is exploring combination therapy with CS0159 and GLP-1 receptor agonists, aiming to enhance weight management and improve liver fat degeneration and inflammation, providing new treatment strategies for metabolic diseases [3]. Financing Purpose - The recent financing will primarily focus on two key areas: accelerating the global multi-center Phase III clinical trials for MASH, PBC, and obesity, and expanding the pipeline of potential best-in-class/first-in-class therapies in the metabolic disease field [4]. - The founder of Kaishikadi expressed gratitude to both new and existing shareholders for their support, emphasizing the commitment to long-term innovation and addressing unmet medical needs in metabolic diseases [4]. Investor Insights - The managing director of Gaorong Capital highlighted the significant unmet needs in the metabolic disease sector and expressed confidence in Kaishikadi's potential to become a global leader in this field, driven by the team's dedication and resilience in advancing multiple candidate pipelines to critical clinical research stages [5].

Core Insights - Kaishikedi has recently completed a new financing round of nearly 500 million yuan, led by Zhongping Capital, with participation from multiple investment institutions including Guoshou Capital and QDGC [2][3] - Over the past 10 months, Kaishikedi has raised a total of nearly 1 billion yuan [3] Company Overview - Established in 2017, Kaishikedi is a clinical-stage biotechnology company focused on diseases related to bile acid metabolism disorders [3] - The company is developing innovative drugs targeting nuclear receptors and G protein-coupled receptors (GPCRs), initially focusing on primary biliary cholangitis (PBC) and expanding into metabolic diseases such as metabolic-associated fatty liver disease (MASH), obesity, and diabetes [3] Use of Funds - The recent financing will primarily be used to accelerate the global multi-center Phase III clinical trials for its lead pipeline, targeting global registration for MASH, PBC, and obesity [3] - Additionally, the funds will support the expansion of the research pipeline to develop a series of potential best-in-class/first-in-class therapies in the metabolic disease field [3] Clinical Progress - Kaishikedi's core product CS0159 has received breakthrough therapy designation and orphan drug status from the FDA, achieving significant progress in clinical trials [3] - The oral formulation has successfully completed Phase II trials for MASH in the U.S., and the Phase II core study for PBC has concluded, with Phase III trials currently underway [3] - The research team is also exploring combination therapy with CS0159 and GLP-1 receptor agonists, aiming to enhance weight management and improve liver fat degeneration and inflammation [3] Leadership Statement - Dr. Xu Huaqiang, the founder of Kaishikedi, expressed optimism about accelerating the clinical development and commercialization of CS0159 with the support of both new and existing shareholders, emphasizing the company's commitment to innovative therapies for metabolic diseases [4]